Bio-Briefing - Quality initiatives: Transformation and Training for Building Business Value

Bio-Briefing - Quality initiatives: Transformation and Training for Building Business Value

October 20, 2015

On 20th October 2015, Trajan hosted a BioMelbourne Network Bio-Briefing event at their corporate headquarters in Ringwood, Melbourne, Victoria – “Quality initiatives: Transformation and Training for Building Business Value”.  

Approximately 25 BioMelbourne members attended to gain insights on industry quality incentives and issues, with presentations delivered by: 

• Mr David Spaulding, Senior Consultant and Training Manager, SeerPharma

Mr Spaulding presented an overview of methods to reducing errors through best practise training and highlighted how the inability to incorporate systematic processes can have a draining effect on the value of businesses.

• Mr Steven van Winckel, General Manager, Glass Technologies, Trajan Scientific and Medical

Mr van Winckel’s presentation concentrated on quality initiatives for manufacturing transformation, and outlined the importance of data collection to analyze production issues leading to the implementation of better work practices to reduce waste, decrease productivity costs and increase department efficiencies.

Attendees also had the opportunity to experience a short tour of Trajan's Ringwood manufacturing facility and witness first-hand how some of the incentives discussed have been implemented within the Glass Technologies business unit.

This event was another mechanism showcasing Trajan’s desire to collaborate with industry partners to promote life science activities and stimulate local interaction to enhance industry success.

BioMelbourne Network Chief Executive Officer Dr Krystal Evans welcomes guests to Trajan Scientific and Medical
Photo: BioMelbourne Network Chief Executive Officer Dr Krystal Evans welcomes guests to Trajan Scientific and Medical

More information
BioMelbourne Network




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More